Vorasidenib for IDH-mutant Grade 2 glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a slow-growing brain tumor called a Grade 2 astrocytoma or oligodendroglioma.
- Your tumor has an IDH1 or IDH2 mutation (a specific genetic change).
- You have already had surgery to remove or biopsy the tumor.
- Your doctor has decided that you do not need radiation or chemotherapy right now, and that vorasidenib is a good option for you.
- You are willing to fill out questionnaires about your well-being in German.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug vorasidenib, guided by a special PET scan, can help people with certain low-grade brain tumors that have come back or are still present after surgery. It aims to see if this approach is safe and effective.
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
This trial tests a new targeted therapy called safusidenib for people whose brain tumor (glioma) has an IDH1 mutation and who have already taken vorasidenib but the tumor kept growing. The study aims to see if safusidenib can help when vorasidenib stops working.
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
This trial tests how well different doses of a new drug, BI 764532, are tolerated by people with a specific type of brain tumor (glioma) that has not responded to standard treatments. The drug targets a protein on the tumor cells, which may help slow tumor growth.
This trial tests a drug called safusidenib, which targets a specific genetic change (IDH1 mutation) in certain grade 3 brain tumors. The drug is given as a pill and may help slow or stop tumor growth, especially when started early.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.